Headlines about Intellia Therapeutics (NASDAQ:NTLA) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intellia Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.361308918205 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities analysts have issued reports on the company. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. TheStreet cut Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. BidaskClub cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Zacks Investment Research upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, ValuEngine cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $30.17.

Intellia Therapeutics (NTLA) opened at $19.43 on Monday. The firm has a market capitalization of $701.15, a PE ratio of -12.46 and a beta of 1.73. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The company had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. Intellia Therapeutics’s revenue for the quarter was up 49.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) EPS. equities analysts forecast that Intellia Therapeutics will post -1.68 earnings per share for the current year.

In related news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nessan Bermingham sold 111,500 shares of Intellia Therapeutics stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now owns 696,000 shares of the company’s stock, valued at approximately $14,156,640. The disclosure for this sale can be found here. Insiders sold a total of 1,971,283 shares of company stock valued at $37,137,161 in the last 90 days. 12.80% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/01/22/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-intellia-therapeutics-ntla-stock-price.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Insider Buying and Selling by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.